<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="brief-report"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Qual Life Res</journal-id><journal-title-group><journal-title>Quality of Life Research</journal-title></journal-title-group><issn pub-type="ppub">0962-9343</issn><issn pub-type="epub">1573-2649</issn><publisher><publisher-name>Springer Netherlands</publisher-name><publisher-loc>Dordrecht</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">20155327</article-id><article-id pub-id-type="pmc">2852524</article-id><article-id pub-id-type="publisher-id">9604</article-id><article-id pub-id-type="doi">10.1007/s11136-010-9604-x</article-id><article-categories><subj-group subj-group-type="heading"><subject>Brief Communication</subject></subj-group></article-categories><title-group><article-title>No negative effects of a multi-factorial, intensified treatment on self-reported health status, treatment satisfaction, and diabetes-related distress in screen-detected type 2 diabetes patients. The ADDITION-Netherlands study</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>van den Donk</surname><given-names>Maureen</given-names></name><address><phone>+31-88-7568154</phone><fax>+31-88-7568099</fax><email>m.vandendonk@umcutrecht.nl</email></address><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Gorter</surname><given-names>Kees J.</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Rutten</surname><given-names>Guy E.</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><aff id="Aff1">Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Str. 6.131, P.O. Box 85500, 3508 GA Utrecht, The Netherlands </aff></contrib-group><pub-date pub-type="epub"><day>13</day><month>2</month><year>2010</year></pub-date><pub-date pub-type="pmc-release"><day>13</day><month>2</month><year>2010</year></pub-date><pub-date pub-type="ppub"><month>5</month><year>2010</year></pub-date><volume>19</volume><issue>4</issue><fpage>509</fpage><lpage>513</lpage><history><date date-type="accepted"><day>27</day><month>1</month><year>2010</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2010</copyright-statement></permissions><abstract><sec><title>Purpose</title><p>To examine the effects of a multi-factorial, intensified treatment on self-reported health status, treatment satisfaction, and diabetes-related distress in screen-detected type 2 diabetes patients.</p></sec><sec><title>Methods</title><p>Cluster-randomised controlled trial; A total of 498 screen-detected type 2 diabetes patients from 79 general practices were assigned to intensified (<italic>n</italic>&#x000a0;=&#x000a0;255) or routine treatment according to Dutch guidelines (<italic>n</italic>&#x000a0;=&#x000a0;243). At baseline and after 3&#x000a0;years, patients completed the Short Form-36 and the European Quality of Life-5 Dimensions questionnaires. After 4.5&#x000a0;years, patients completed the Diabetes Treatment Satisfaction Questionnaire and the Problem Areas In Diabetes scale. We analysed the effects of intensified treatment on self-rated health status, treatment satisfaction, and diabetes-related distress, using random effects models to account for clustering at practice level.</p></sec><sec><title>Results</title><p>Three to 5&#x000a0;years after type 2 diabetes was detected by screening, there were no differences between intensified and routine treatment in self-reported health status, treatment satisfaction, and diabetes-related distress.</p></sec><sec><title>Conclusions</title><p>Multi-factorial, intensified treatment did not influence self-rated health status, treatment satisfaction, and distress in screen-detected type 2 diabetes patients. Therefore, health care professionals do not have to fear negative effects of an intensified treatment on these psychological outcomes.</p></sec></abstract><kwd-group><title>Keywords</title><kwd>Randomised controlled trial</kwd><kwd>Diabetes mellitus, type 2</kwd><kwd>Intensified treatment</kwd><kwd>Primary health care</kwd><kwd>Health status</kwd><kwd>Treatment satisfaction</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; Springer Science+Business Media B.V. 2010</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><p>Type 2 diabetes mellitus (T2DM) is related to worsened psychological outcomes, especially in case of complications [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR2">2</xref>], but the effects of intensive treatment are not known. Intensive treatment of hyperglycaemia, hypertension, and dyslipidaemia can reduce cardiovascular disease in T2DM patients on the long run [<xref ref-type="bibr" rid="CR3">3</xref>] and thus may improve psychological outcomes. However, T2DM patients may experience the need to take large quantities of medication as a burden, which can lead to psychosocial stress [<xref ref-type="bibr" rid="CR4">4</xref>] and presumably less satisfaction with treatment. This may especially be so in screen-detected patients, who do not have complaints, but still have to take medication. Examination of psychological outcomes showed that in screen-detected patients, intensified treatment led to more anxiety and less self-efficacy in the first year after diagnosis [<xref ref-type="bibr" rid="CR5">5</xref>]. The UK Prospective Diabetes Study (UKPDS) found no impact of intensified treatment on perceived health in screen-detected patients, although health status was affected by complications of the disease [<xref ref-type="bibr" rid="CR6">6</xref>].</p><p>In the ADDITION study (Anglo-Danish-Dutch Study of Intensive Treatment in People with Screen-Detected Diabetes in Primary Care), an intensified, multi-factorial treatment of screen-detected T2DM patients is compared with usual care according to national guidelines [<xref ref-type="bibr" rid="CR7">7</xref>]. In the current study, we investigated the effects of 3&#x02013;4&#x000a0;years of intensified pharmacological treatment combined with lifestyle advices on self-reported health status, treatment satisfaction, and diabetes-related distress in screen-detected T2DM patients in the ADDITION-Netherlands study. The follow-up period might be too short to detect differences in complications. Treatment targets are stricter than in the UKPDS, which may lead to more hypoglycaemic events and a larger burden of treatment and thus might influence psychological outcomes negatively.</p></sec><sec id="Sec2" sec-type="methods"><title>Methods</title><p>The current study is part of the ongoing international ADDITION study in 3,057 screen-detected T2DM patients, classified according to the 1999 WHO diagnostic criteria [<xref ref-type="bibr" rid="CR8">8</xref>]. ADDITION consists of a screening study and a subsequent intervention study with a mean follow-up of 5&#x000a0;years, with a composite endpoint comprised of cardiovascular mortality and morbidity, revascularisations, and amputations as the primary outcome measure [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR9">9</xref>]. The ADDITION-Netherlands study was approved by the medical-ethical committee of the University Medical Center Utrecht. In a stepwise population-based screening programme (2002&#x02013;2004) in 56,978 non-diabetic patients, aged 50&#x02013;70&#x000a0;years, from 79 general practices in the south-western region of the Netherlands, we detected 586 new T2DM patients [<xref ref-type="bibr" rid="CR10">10</xref>]. Of them, 498 were included in a single-blind trial with practice level randomisation to intensified multi-factorial treatment (IT; <italic>n</italic>&#x000a0;=&#x000a0;255) or routine care (RC; <italic>n</italic>&#x000a0;=&#x000a0;243). The other 88 patients declined participation (<italic>n</italic>&#x000a0;=&#x000a0;69) or did not meet the eligibility criteria (<italic>n</italic>&#x000a0;=&#x000a0;19). Patients were blinded to which treatment arm their general practitioner had been randomised. Participants gave written informed consent [<xref ref-type="bibr" rid="CR11">11</xref>].</p><p>The IT protocol was target-driven. The treatment targets are HbA<sub>1c</sub>&#x000a0;&#x0003c;7.0%, but alterations to glucose-lowering therapy when HbA<sub>1c</sub>&#x000a0;&#x0003e;6.5%; blood pressure&#x000a0;&#x02264;135/85&#x000a0;mmHg, but prescription of an ACE-inhibitor when blood pressure&#x000a0;&#x0003e;120/80&#x000a0;mmHg; prescription of acetylsalicylic acid 80&#x000a0;mg per day for patients treated with an antihypertensive agent; total cholesterol&#x000a0;&#x02264;3.5&#x000a0;mmol/l [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR11">11</xref>]. Treatment goals in the RC group, originally according to the 1999 guidelines of the Dutch College of General Practitioners, were revised in 2006, but still less strict than the IT protocol: HbA1c&#x000a0;&#x02264;7%, systolic blood pressure&#x000a0;&#x02264;140&#x000a0;mmHg, total cholesterol&#x000a0;&#x02264;4.5&#x000a0;mmol/l, and LDL-cholesterol&#x000a0;&#x02264;2.5&#x000a0;mmol/l; no acetylsalicylic acid had to be prescribed [<xref ref-type="bibr" rid="CR12">12</xref>].</p><p>Prior to entry into the study and after 3&#x000a0;years, participants completed the Medical Outcomes Study 36-Item Short Form Health Survey (SF-36) [<xref ref-type="bibr" rid="CR13">13</xref>] and the European Quality of Life-5 Dimensions (EQ5D) [<xref ref-type="bibr" rid="CR14">14</xref>] questionnaires. The SF-36 is a 36-item questionnaire that measures perceived health, encompassing eight dimensions: general health, vitality, mental health, physical functioning, limitations due to physical difficulties (role physical), bodily pain, social functioning, and limitations due to emotional difficulties (role emotional) [<xref ref-type="bibr" rid="CR13">13</xref>]. For each dimension, item scores are transformed to a scale ranging from 0 (worst health) to 100 (best health). The Dutch version has been shown to be valid and reliable [<xref ref-type="bibr" rid="CR15">15</xref>]. The EQ5D is a measure of perceived health including five dimensions: mobility, self care, usual activities, pain/discomfort, and anxiety/depression [<xref ref-type="bibr" rid="CR14">14</xref>]. Each dimension has three levels: no, some, and severe limitations. So, there are 243 (i.e., 3<sup>5</sup>) possible sets of values for the EQ5D. All of these possible health states have been valued by the general public, ranging from &#x02212;0.549 for severe problems with all dimensions to 1 for full health. Values found in the UK have been validated for the Netherlands.</p><p>After 4.5&#x000a0;years, participants completed the Diabetes Treatment Satisfaction Questionnaire (DTSQ) [<xref ref-type="bibr" rid="CR16">16</xref>] and the Problem Areas In Diabetes scale (PAID) [<xref ref-type="bibr" rid="CR17">17</xref>]. The DTSQ contains a six-item scale assessing treatment satisfaction. Each item is scored on a scale of 0&#x02013;6; thus the total score of the DTSQ ranges between 0 and 36, with higher scores indicating greater satisfaction with treatment [<xref ref-type="bibr" rid="CR16">16</xref>]. The PAID is a self-report measure of diabetes-related distress, consisting of 20 statements that were identified as common negative emotions related to living with diabetes [<xref ref-type="bibr" rid="CR17">17</xref>]. Each item can be rated on a 5-point Likert scale ranging from 0 (&#x0201c;not a problem&#x0201d;) to 4 (&#x0201c;a serious problem&#x0201d;). The total score is transformed to a 0&#x02013;100 scale, with higher scores indicating higher emotional distress. The Dutch version of the PAID has good internal consistency and factorial validity [<xref ref-type="bibr" rid="CR18">18</xref>].</p><p>We analysed differences (IT&#x02013;RC) in changes from baseline to the 3-year measurement in the SF-36 and EQ5D scores. For effects on treatment satisfaction and diabetes-related emotional distress, we analysed differences (IT&#x02013;RC) in the scores of the DTSQ and PAID scales after 4.5&#x000a0;years. We used random effects models to account for clustering at the level of the general practitioner. We calculated 95% confidence intervals for the differences between treatment arms and used a two-sided alpha of 0.05 to test significance. A formal power calculation was not carried out as these patient-reported outcome measures were not the primary outcome measures for the intervention study.</p></sec><sec id="Sec3"><title>Results</title><p>Response rates for the different scores varied between 60 and 72% and did not differ for the IT and RC groups. The IT and RC groups are well comparable with respect to clinical, biochemical, and behavioural characteristics at baseline [<xref ref-type="bibr" rid="CR11">11</xref>]. This did not change when only people who completed the questionnaires were taken into account, except for systolic blood pressure (mean IT: 167.6&#x000a0;mmHg; RC: 162.3&#x000a0;mmHg; <italic>P</italic>&#x000a0;=&#x000a0;0.03) and mental health (<italic>P</italic>&#x000a0;=&#x000a0;0.03; Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>).<table-wrap id="Tab1"><label>Table&#x000a0;1</label><caption><p>SF-36 and EQ5D scores: changes within groups 3&#x000a0;years after screen-detection of diabetes and differences in changes between groups (IT-RC). DTSQ and PAID scores at 4.5&#x000a0;years after screen-detection of diabetes: differences between groups (IT-RC)</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2"/><th align="left" colspan="4">Intensified treatment (IT)</th><th align="left" colspan="4">Routine care (RC)</th><th align="left" rowspan="2">Difference</th></tr><tr><th align="left"><italic>N</italic></th><th align="left">Baseline</th><th align="left">Follow-up</th><th align="left">Change</th><th align="left"><italic>N</italic></th><th align="left">Baseline</th><th align="left">Follow-up</th><th align="left">Change</th></tr></thead><tbody><tr><td align="left">SF-36 PF</td><td align="left">171</td><td align="left">77.6&#x000a0;&#x000b1;&#x000a0;1.7</td><td char="&#x000b1;" align="char">77.3&#x000a0;&#x000b1;&#x000a0;1.8</td><td align="left">&#x02212;0.3 (&#x02212;3.4;2.8)</td><td char="." align="char">156</td><td align="left">78.4&#x000a0;&#x000b1;&#x000a0;1.8</td><td char="&#x000b1;" align="char">79.1&#x000a0;&#x000b1;&#x000a0;1.7</td><td align="left">0.7 (&#x02212;2.5;3.8)</td><td char="(" align="char">&#x02212;1.2 (&#x02212;6.1;3.7)</td></tr><tr><td align="left">SF-36 RP</td><td align="left">171</td><td align="left">83.8&#x000a0;&#x000b1;&#x000a0;2.3</td><td char="&#x000b1;" align="char">76.6&#x000a0;&#x000b1;&#x000a0;2.7</td><td align="left">&#x02212;7.3 (&#x02212;12.4;&#x02212;2.1)<sup>&#x02021;</sup></td><td char="." align="char">156</td><td align="left">85.4&#x000a0;&#x000b1;&#x000a0;2.4</td><td char="&#x000b1;" align="char">83.4&#x000a0;&#x000b1;&#x000a0;2.4</td><td align="left">&#x02212;2.0 (&#x02212;7.0;3.0)</td><td char="(" align="char">&#x02212;5.3 (&#x02212;12.5;1.9)</td></tr><tr><td align="left">SF-36 BP</td><td align="left">178</td><td align="left">80.5&#x000a0;&#x000b1;&#x000a0;1.7</td><td char="&#x000b1;" align="char">78.0&#x000a0;&#x000b1;&#x000a0;1.8</td><td align="left">&#x02212;2.5 (&#x02212;5.7;0.7)</td><td char="." align="char">163</td><td align="left">84.7&#x000a0;&#x000b1;&#x000a0;1.7</td><td char="&#x000b1;" align="char">81.1&#x000a0;&#x000b1;&#x000a0;1.6</td><td align="left">&#x02212;3.6 (&#x02212;6.8;&#x02212;0.4)<sup>&#x02020;</sup></td><td char="(" align="char">1.1 (&#x02212;3.4;5.6)</td></tr><tr><td align="left">SF-36 GH</td><td align="left">161</td><td align="left">59.5&#x000a0;&#x000b1;&#x000a0;0.9</td><td char="&#x000b1;" align="char">64.2&#x000a0;&#x000b1;&#x000a0;1.5</td><td align="left">4.7 (2.3&#x02212;7.2)<sup>&#x000a7;</sup></td><td char="." align="char">145</td><td align="left">59.6&#x000a0;&#x000b1;&#x000a0;1.0</td><td char="&#x000b1;" align="char">65.8&#x000a0;&#x000b1;&#x000a0;1.5</td><td align="left">6.2 (3.7&#x02212;8.7)<sup>||</sup></td><td char="(" align="char">&#x02212;1.5 (&#x02212;5.0;2.0)</td></tr><tr><td align="left">SF-36 VT</td><td align="left">163</td><td align="left">49.2&#x000a0;&#x000b1;&#x000a0;1.1</td><td char="&#x000b1;" align="char">65.6&#x000a0;&#x000b1;&#x000a0;1.6</td><td align="left">16.4 (13.0;19.7)<sup>||</sup></td><td char="." align="char">155</td><td align="left">51.4&#x000a0;&#x000b1;&#x000a0;1.1</td><td char="&#x000b1;" align="char">67.7&#x000a0;&#x000b1;&#x000a0;1.6</td><td align="left">16.3 (13.4;19.2)<sup>||</sup></td><td char="(" align="char">0.03 (-4.6;4.7)</td></tr><tr><td align="left">SF-36 SF</td><td align="left">160</td><td align="left">89.3&#x000a0;&#x000b1;&#x000a0;1.4</td><td char="&#x000b1;" align="char">83.2&#x000a0;&#x000b1;&#x000a0;1.7</td><td align="left">&#x02212;6.1 (&#x02212;9.4;&#x02212;2.8)<sup>&#x000a7;</sup></td><td char="." align="char">150</td><td align="left">90.0&#x000a0;&#x000b1;&#x000a0;1.3</td><td char="&#x000b1;" align="char">86.2&#x000a0;&#x000b1;&#x000a0;1.6</td><td align="left">&#x02212;3.8 (&#x02212;6.8;&#x02212;0.9)<sup>&#x02020;</sup></td><td char="(" align="char">&#x02212;2.3 (&#x02212;7.0;2.3)</td></tr><tr><td align="left">SF-36 RE</td><td align="left">172</td><td align="left">89.3&#x000a0;&#x000b1;&#x000a0;2.1</td><td char="&#x000b1;" align="char">84.8&#x000a0;&#x000b1;&#x000a0;2.4</td><td align="left">&#x02212;4.6 (&#x02212;10.3;1.1)</td><td char="." align="char">157</td><td align="left">87.9&#x000a0;&#x000b1;&#x000a0;2.4</td><td char="&#x000b1;" align="char">87.0&#x000a0;&#x000b1;&#x000a0;2.4</td><td align="left">&#x02212;0.8 (&#x02212;5.6;3.9)</td><td char="(" align="char">&#x02212;3.7 (&#x02212;11.2;3.7)</td></tr><tr><td align="left">SF-36 MH</td><td align="left">172</td><td align="left">68.1&#x000a0;&#x000b1;&#x000a0;1.0</td><td char="&#x000b1;" align="char">75.9&#x000a0;&#x000b1;&#x000a0;1.4</td><td align="left">7.8 (5.1;10.5)<sup>||</sup></td><td char="." align="char">160</td><td align="left">71.1&#x000a0;&#x000b1;&#x000a0;0.9<sup>*</sup></td><td char="&#x000b1;" align="char">79.7&#x000a0;&#x000b1;&#x000a0;1.2</td><td align="left">8.6 (6.1;11.1)<sup>||</sup></td><td char="(" align="char">&#x02212;0.8 (&#x02212;4.5;2.8)</td></tr><tr><td align="left">EQ5D</td><td align="left">171</td><td align="left">0.81&#x000a0;&#x000b1;&#x000a0;0.02</td><td char="&#x000b1;" align="char">0.81&#x000a0;&#x000b1;&#x000a0;0.02</td><td align="left">0.0002 (&#x02212;0.03;0.03)</td><td char="." align="char">157</td><td align="left">0.81&#x000a0;&#x000b1;&#x000a0;0.02</td><td char="&#x000b1;" align="char">0.82&#x000a0;&#x000b1;&#x000a0;0.02</td><td align="left">0.001 (&#x02212;0.03;0.03)</td><td char="(" align="char">&#x02212;0.002 (&#x02212;0.04;0.04)</td></tr><tr><td align="left">DTSQ</td><td align="left">184</td><td align="left">n.a.</td><td char="&#x000b1;" align="char">32.7&#x000a0;&#x000b1;&#x000a0;0.3</td><td align="left">n.a.</td><td char="." align="char">162</td><td align="left">n.a.</td><td char="&#x000b1;" align="char">32.7&#x000a0;&#x000b1;&#x000a0;0.3</td><td align="left">n.a.</td><td char="(" align="char">&#x02212;0.05 (&#x02212;0.9;0.8)</td></tr><tr><td align="left">PAID</td><td align="left">177</td><td align="left">n.a.</td><td char="&#x000b1;" align="char">9.8&#x000a0;&#x000b1;&#x000a0;1.0</td><td align="left">n.a.</td><td char="." align="char">164</td><td align="left">n.a.</td><td char="&#x000b1;" align="char">8.4&#x000a0;&#x000b1;&#x000a0;0.9</td><td align="left">n.a.</td><td char="(" align="char">1.4 (&#x02212;1.2;4.0)</td></tr></tbody></table><table-wrap-foot><p>Data are mean&#x000a0;&#x000b1;&#x000a0;SEM or mean (95% CI)</p><p><italic>IT</italic> intensified multi-factorial treatment, <italic>RC</italic> routine care, <italic>SF</italic>-<italic>36</italic> medical outcomes study 36-item short form health survey, <italic>PF</italic> physical functioning, <italic>RP</italic> role physical, limitations due to physical difficulties, <italic>BP</italic> bodily pain, <italic>GH</italic> general health, <italic>VT</italic> vitality, <italic>SF</italic> social functioning, <italic>RE</italic> role emotional, limitations due to emotional difficulties, <italic>MH</italic> mental health, <italic>EQ5D</italic> European quality of life-5 dimensions, <italic>DTSQ</italic> diabetes treatment satisfaction questionnaire, <italic>PAID</italic> problem areas in diabetes scale, <italic>n.a.</italic> not applicable</p><p>*&#x000a0;Statistically significant difference at baseline between IT and RC groups, <italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.05</p><p>&#x02020;&#x000a0;Statistically significant difference between baseline and follow-up, <italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.05</p><p>&#x02021;&#x000a0;Statistically significant difference between baseline and follow-up, <italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.01</p><p>&#x000a7;&#x000a0;Statistically significant difference between baseline and follow-up, <italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.001</p><p>||&#x000a0;Statistically significant difference between baseline and follow-up, <italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.0001</p></table-wrap-foot></table-wrap></p><p>After 3&#x000a0;years (mean 2.97; SD 0.26), scores increased on the SF-36 scales general health, vitality, and mental health and decreased on the SF-36 scales role physical (statistically significant in IT), bodily pain (statistically significantly in RC), and social functioning. None of the changes in SF-36 or EQ5D differed significantly between IT and RC (Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>).</p><p>Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref> also displays the DTSQ and PAID scores at 4.5&#x000a0;years (mean 4.69; SD 0.62) in both treatment groups, showing no differences between IT and RC.</p></sec><sec id="Sec4"><title>Discussion</title><p>This study showed no effects of intensified treatment on self-reported health status, satisfaction with diabetes treatment, and diabetes-related emotional distress. We examined a large group of screen-detected T2DM patients, who were followed until 3&#x02013;5&#x000a0;years after diagnosis. The results address both diabetes-specific and generic outcomes [<xref ref-type="bibr" rid="CR19">19</xref>] and are highly relevant for patients.</p><p>To our knowledge, the ADDITION study is the first randomised trial on the effects of an intensified, multi-factorial intervention in T2DM patients identified by screening. Until now, only few randomised controlled trials compared a multi-factorial treatment with a standard treatment of T2DM, [<xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR20">20</xref>]. The UKPDS showed no effects of intensive treatment on perceived health [<xref ref-type="bibr" rid="CR6">6</xref>]. M&#x000e9;nard et al. reported effects on quality of life in poorly controlled patients with a longer duration of diabetes using an adapted version of the Diabetes Quality of Life Measure [<xref ref-type="bibr" rid="CR21">21</xref>], indicating an improvement after 1&#x000a0;year in general quality of life and life satisfaction, but not in diabetes-related worry [<xref ref-type="bibr" rid="CR20">20</xref>]. However, due to the shorter follow-up period and different study population, these results are hard to compare with ours.</p><p>A limitation might be the response rates. However, these are in accordance with or even higher than in other studies in the Netherlands [<xref ref-type="bibr" rid="CR22">22</xref>]. Response rates were comparable for IT and RC groups, and responders did not differ from non-responders (results not shown). With the included numbers of patients, we were able to detect differences up to 7%, which was reported as a moderate effect [<xref ref-type="bibr" rid="CR15">15</xref>], on all of the reported scales except for SF-36 role physical and role emotional (each 10%).</p><p>Another limitation might be that it was not possible to include the DTSQ and PAID at baseline, as the patients were screen-detected and did not know that they had T2DM at that time. We cannot be sure whether patients in both groups are similar with respect to what they would have thought about treatment satisfaction or diabetes-related distress. However, as patients in the IT and RC groups were well comparable with respect to clinical, biochemical, and behavioural characteristics at baseline [<xref ref-type="bibr" rid="CR11">11</xref>], we have no indications that there would have been large differences in baseline DTSQ and PAID values.</p><p>The scores on SF-36, EQ5D, PAID, and DTSQ indicate an overall good psychological state of the participants, probably because all patients are screen-detected. As a consequence, patients have diabetes for only a few years, with a few complications accordingly.</p><p>The finding that nor self-reported health status nor treatment satisfaction or diabetes-related distress was influenced by a multi-factorial intensification of treatment does imply that health care professionals do not have to fear negative effects of an intensive treatment starting immediately after diagnosing T2DM. Assuming that an intensified treatment may decrease the risk of complications compared to routine care, one could expect a difference between both groups on the long run in favour of the people who were treated intensively after their screen-detected diagnosis. Patients should be followed up for a longer period to assess the full impact on psychological outcomes of screening for T2DM immediately followed by intensified, multi-factorial treatment.</p></sec></body><back><ack><p>The ADDITION-Netherlands study is made possible by unrestricted grants from Novo Nordisk and Glaxo Smith Kline. For the current analyses, we received a grant from the Dutch Diabetes Research Foundation (grant number 2007.13.001).</p><p><bold>Open Access</bold> This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.</p></ack><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Redekop</surname><given-names>WK</given-names></name><name><surname>Koopmanschap</surname><given-names>MA</given-names></name><name><surname>Stolk</surname><given-names>RP</given-names></name><name><surname>Rutten</surname><given-names>GE</given-names></name><name><surname>Wolffenbuttel</surname><given-names>BH</given-names></name><name><surname>Niessen</surname><given-names>LW</given-names></name></person-group><article-title>Health-related quality of life and treatment satisfaction in Dutch patients with type 2 diabetes</article-title><source>Diabetes Care</source><year>2002</year><volume>25</volume><issue>3</issue><fpage>458</fpage><lpage>463</lpage><pub-id pub-id-type="doi">10.2337/diacare.25.3.458</pub-id><pub-id pub-id-type="pmid">11874930</pub-id></mixed-citation></ref><ref id="CR2"><label>2.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rubin</surname><given-names>RR</given-names></name><name><surname>Peyrot</surname><given-names>M</given-names></name></person-group><article-title>Quality of life and diabetes</article-title><source>Diabetes Metabolism Research Review</source><year>1999</year><volume>15</volume><issue>3</issue><fpage>205</fpage><lpage>218</lpage><pub-id pub-id-type="doi">10.1002/(SICI)1520-7560(199905/06)15:3&#x0003c;205::AID-DMRR29&#x0003e;3.0.CO;2-O</pub-id></mixed-citation></ref><ref id="CR3"><label>3.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gaede</surname><given-names>P</given-names></name><name><surname>Vedel</surname><given-names>P</given-names></name><name><surname>Larsen</surname><given-names>N</given-names></name><name><surname>Jensen</surname><given-names>GV</given-names></name><name><surname>Parving</surname><given-names>HH</given-names></name><name><surname>Pedersen</surname><given-names>O</given-names></name></person-group><article-title>Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes</article-title><source>New England Journal of Medicine</source><year>2003</year><volume>348</volume><issue>5</issue><fpage>383</fpage><lpage>393</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa021778</pub-id><pub-id pub-id-type="pmid">12556541</pub-id></mixed-citation></ref><ref id="CR4"><label>4.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peyrot</surname><given-names>M</given-names></name><name><surname>Rubin</surname><given-names>RR</given-names></name><name><surname>Lauritzen</surname><given-names>T</given-names></name><name><surname>Snoek</surname><given-names>FJ</given-names></name><name><surname>Matthews</surname><given-names>DR</given-names></name><name><surname>Skovlund</surname><given-names>SE</given-names></name></person-group><article-title>Psychosocial problems and barriers to improved diabetes management: Results of the cross-national diabetes attitudes, wishes and needs (DAWN) study</article-title><source>Diabetic Medicine</source><year>2005</year><volume>22</volume><issue>10</issue><fpage>1379</fpage><lpage>1385</lpage><pub-id pub-id-type="doi">10.1111/j.1464-5491.2005.01644.x</pub-id><pub-id pub-id-type="pmid">16176200</pub-id></mixed-citation></ref><ref id="CR5"><label>5.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thoolen</surname><given-names>BJ</given-names></name><name><surname>Ridder</surname><given-names>DT</given-names></name><name><surname>Bensing</surname><given-names>JM</given-names></name><name><surname>Gorter</surname><given-names>KJ</given-names></name><name><surname>Rutten</surname><given-names>GE</given-names></name></person-group><article-title>Psychological outcomes of patients with screen-detected type 2 diabetes: The influence of time since diagnosis and treatment intensity</article-title><source>Diabetes Care</source><year>2006</year><volume>29</volume><issue>10</issue><fpage>2257</fpage><lpage>2262</lpage><pub-id pub-id-type="doi">10.2337/dc06-0617</pub-id><pub-id pub-id-type="pmid">17003303</pub-id></mixed-citation></ref><ref id="CR6"><label>6.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><collab>UK Prospective Diabetes Study (UKPDS) Group</collab></person-group><article-title>Quality of life in type 2 diabetic patients is affected by complications but not by intensive policies to improve blood glucose or blood pressure control (UKPDS 37). U.K. prospective diabetes study group</article-title><source>Diabetes Care</source><year>1999</year><volume>22</volume><issue>7</issue><fpage>1125</fpage><lpage>1136</lpage><pub-id pub-id-type="doi">10.2337/diacare.22.7.1125</pub-id><pub-id pub-id-type="pmid">10388978</pub-id></mixed-citation></ref><ref id="CR7"><label>7.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lauritzen</surname><given-names>T</given-names></name><name><surname>Griffin</surname><given-names>S</given-names></name><name><surname>Borch-Johnsen</surname><given-names>K</given-names></name><name><surname>Wareham</surname><given-names>NJ</given-names></name><name><surname>Wolffenbuttel</surname><given-names>BH</given-names></name><name><surname>Rutten</surname><given-names>G</given-names></name></person-group><article-title>The ADDITION study: Proposed trial of the cost-effectiveness of an intensive multifactorial intervention on morbidity and mortality among people with Type 2 diabetes detected by screening</article-title><source>International Journal of Obesity Related Metabolic Disorder</source><year>2000</year><volume>24</volume><issue>3</issue><fpage>S6</fpage><lpage>S11</lpage><pub-id pub-id-type="doi">10.1038/sj/ijo/0801420</pub-id></mixed-citation></ref><ref id="CR8"><label>8.</label><mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Alberti</surname><given-names>KGMM</given-names></name><name><surname>Zimmet</surname><given-names>PZ</given-names></name></person-group><source>Definition, diagnosis and classification of diabetes mellitus and its complications</source><year>1999</year><publisher-loc>Geneva</publisher-loc><publisher-name>World Health Organization</publisher-name></mixed-citation></ref><ref id="CR9"><label>9.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sandbaek</surname><given-names>A</given-names></name><name><surname>Griffin</surname><given-names>SJ</given-names></name><name><surname>Rutten</surname><given-names>G</given-names></name><name><surname>Davies</surname><given-names>M</given-names></name><name><surname>Stolk</surname><given-names>R</given-names></name><name><surname>Khunti</surname><given-names>K</given-names></name><etal/></person-group><article-title>Stepwise screening for diabetes identifies people with high but modifiable coronary heart disease risk. The ADDITION study</article-title><source>Diabetologia</source><year>2008</year><volume>51</volume><issue>7</issue><fpage>1127</fpage><lpage>1134</lpage><pub-id pub-id-type="doi">10.1007/s00125-008-1013-0</pub-id><pub-id pub-id-type="pmid">18443762</pub-id></mixed-citation></ref><ref id="CR10"><label>10.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Janssen</surname><given-names>PG</given-names></name><name><surname>Gorter</surname><given-names>KJ</given-names></name><name><surname>Stolk</surname><given-names>RP</given-names></name><name><surname>Rutten</surname><given-names>GE</given-names></name></person-group><article-title>Low yield of population-based screening for type 2 diabetes in the Netherlands: The ADDITION Netherlands study</article-title><source>Family Practice</source><year>2007</year><volume>24</volume><issue>6</issue><fpage>555</fpage><lpage>561</lpage><pub-id pub-id-type="doi">10.1093/fampra/cmm052</pub-id><pub-id pub-id-type="pmid">17962235</pub-id></mixed-citation></ref><ref id="CR11"><label>11.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Janssen</surname><given-names>PG</given-names></name><name><surname>Gorter</surname><given-names>KJ</given-names></name><name><surname>Stolk</surname><given-names>RP</given-names></name><name><surname>Rutten</surname><given-names>GE</given-names></name></person-group><article-title>Randomised controlled trial of intensive multifactorial treatment for cardiovascular risk in patients with screen-detected type 2 diabetes: 1-year data from the ADDITION Netherlands study</article-title><source>British Journal of General Practice</source><year>2009</year><volume>59</volume><issue>558</issue><fpage>43</fpage><lpage>48</lpage><pub-id pub-id-type="doi">10.3399/bjgp09X394851</pub-id><pub-id pub-id-type="pmid">19105915</pub-id></mixed-citation></ref><ref id="CR12"><label>12.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rutten</surname><given-names>GEHM</given-names></name><name><surname>Grauw</surname><given-names>WJC</given-names></name><name><surname>Nijpels</surname><given-names>G</given-names></name><name><surname>Goudswaard</surname><given-names>AN</given-names></name><name><surname>Uitewaal</surname><given-names>PJM</given-names></name><name><surname>Does</surname><given-names>FEE</given-names></name><etal/></person-group><article-title>NHG-Guidelines type 2 Diabetes mellitus (second revision)</article-title><source>Huisarts en Wetenschap</source><year>2006</year><volume>49</volume><fpage>137</fpage><lpage>152</lpage></mixed-citation></ref><ref id="CR13"><label>13.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ware</surname><given-names>JE</given-names><suffix>Jr</suffix></name><name><surname>Sherbourne</surname><given-names>CD</given-names></name></person-group><article-title>The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection</article-title><source>Medical Care</source><year>1992</year><volume>30</volume><issue>6</issue><fpage>473</fpage><lpage>483</lpage><pub-id pub-id-type="doi">10.1097/00005650-199206000-00002</pub-id><pub-id pub-id-type="pmid">1593914</pub-id></mixed-citation></ref><ref id="CR14"><label>14.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><collab>The EuroQol Group</collab></person-group><article-title>EuroQol&#x02013;a new facility for the measurement of health-related quality of life</article-title><source>Health Policy</source><year>1990</year><volume>16</volume><issue>3</issue><fpage>199</fpage><lpage>208</lpage><pub-id pub-id-type="doi">10.1016/0168-8510(90)90421-9</pub-id><pub-id pub-id-type="pmid">10109801</pub-id></mixed-citation></ref><ref id="CR15"><label>15.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aaronson</surname><given-names>NK</given-names></name><name><surname>Muller</surname><given-names>M</given-names></name><name><surname>Cohen</surname><given-names>PD</given-names></name><name><surname>Essink-Bot</surname><given-names>ML</given-names></name><name><surname>Fekkes</surname><given-names>M</given-names></name><name><surname>Sanderman</surname><given-names>R</given-names></name><etal/></person-group><article-title>Translation, validation, and norming of the Dutch language version of the SF-36 Health Survey in community and chronic disease populations</article-title><source>Journal of Clinical Epidemiology</source><year>1998</year><volume>51</volume><issue>11</issue><fpage>1055</fpage><lpage>1068</lpage><pub-id pub-id-type="doi">10.1016/S0895-4356(98)00097-3</pub-id><pub-id pub-id-type="pmid">9817123</pub-id></mixed-citation></ref><ref id="CR16"><label>16.</label><mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Bradley</surname><given-names>C</given-names></name></person-group><person-group person-group-type="editor"><name><surname>Bradley</surname><given-names>C</given-names></name></person-group><article-title>Diabetes treatment satisfaction questionnaire</article-title><source>Handbook of psychology and diabetes: A guide to psychological measurement in diabetes research and practice</source><year>1994</year><publisher-loc>Chur, Switzerland</publisher-loc><publisher-name>Harwood Academic</publisher-name><fpage>111</fpage><lpage>132</lpage></mixed-citation></ref><ref id="CR17"><label>17.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Polonsky</surname><given-names>WH</given-names></name><name><surname>Anderson</surname><given-names>BJ</given-names></name><name><surname>Lohrer</surname><given-names>PA</given-names></name><name><surname>Welch</surname><given-names>G</given-names></name><name><surname>Jacobson</surname><given-names>AM</given-names></name><name><surname>Aponte</surname><given-names>JE</given-names></name><name><surname>Schwartz</surname><given-names>CE</given-names></name></person-group><article-title>Assessment of diabetes-related distress</article-title><source>Diabetes Care</source><year>1995</year><volume>18</volume><issue>6</issue><fpage>754</fpage><lpage>760</lpage><pub-id pub-id-type="doi">10.2337/diacare.18.6.754</pub-id><pub-id pub-id-type="pmid">7555499</pub-id></mixed-citation></ref><ref id="CR18"><label>18.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Snoek</surname><given-names>FJ</given-names></name><name><surname>Pouwer</surname><given-names>F</given-names></name><name><surname>Welch</surname><given-names>GW</given-names></name><name><surname>Polonsky</surname><given-names>WH</given-names></name></person-group><article-title>Diabetes-related emotional distress in Dutch and U.S. diabetic patients: Cross-cultural validity of the problem areas in diabetes scale</article-title><source>Diabetes Care</source><year>2000</year><volume>23</volume><issue>9</issue><fpage>1305</fpage><lpage>1309</lpage><pub-id pub-id-type="doi">10.2337/diacare.23.9.1305</pub-id><pub-id pub-id-type="pmid">10977023</pub-id></mixed-citation></ref><ref id="CR19"><label>19.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brommels</surname><given-names>M</given-names></name><name><surname>Sintonen</surname><given-names>H</given-names></name></person-group><article-title>Be generic and specific: Quality of life measurement in clinical studies</article-title><source>Annals of Medicine</source><year>2001</year><volume>33</volume><issue>5</issue><fpage>319</fpage><lpage>322</lpage><pub-id pub-id-type="doi">10.3109/07853890109002084</pub-id><pub-id pub-id-type="pmid">11491189</pub-id></mixed-citation></ref><ref id="CR20"><label>20.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>M&#x000e9;nard</surname><given-names>J</given-names></name><name><surname>Payette</surname><given-names>H</given-names></name><name><surname>Dubuc</surname><given-names>N</given-names></name><name><surname>Baillargeon</surname><given-names>JP</given-names></name><name><surname>Maheux</surname><given-names>P</given-names></name><name><surname>Ardilouze</surname><given-names>JL</given-names></name></person-group><article-title>Quality of life in type 2 diabetes patients under intensive multitherapy</article-title><source>Diabetes Metabolism</source><year>2007</year><volume>33</volume><issue>1</issue><fpage>54</fpage><lpage>60</lpage><pub-id pub-id-type="doi">10.1016/j.diabet.2006.09.001</pub-id><pub-id pub-id-type="pmid">17258926</pub-id></mixed-citation></ref><ref id="CR21"><label>21.</label><mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Jacobson</surname><given-names>AM</given-names></name><collab>The. D. C. C. T. Research Group</collab></person-group><person-group person-group-type="editor"><name><surname>Bradley</surname><given-names>C</given-names></name></person-group><article-title>The diabetes quality of life measure</article-title><source>Handbook of psychology and diabetes: A guide to psychological measurement in diabetes research and practice</source><year>1994</year><publisher-loc>Chur, Switzerland</publisher-loc><publisher-name>Harwood Academic</publisher-name><fpage>65</fpage><lpage>87</lpage></mixed-citation></ref><ref id="CR22"><label>22.</label><mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Brink</surname><given-names>CL</given-names></name><name><surname>Viet</surname><given-names>AL</given-names></name><name><surname>Boshuizen</surname><given-names>HC</given-names></name><name><surname>Ameijden</surname><given-names>EJC</given-names></name><name><surname>Droomers</surname><given-names>M</given-names></name></person-group><source>Methodology of the public health monitor; comparability of data. RIVM report 260854009</source><year>2005</year><publisher-loc>Bilthoven</publisher-loc><publisher-name>RIVM</publisher-name></mixed-citation></ref></ref-list><glossary><title>Abbreviations</title><def-list><def-item><term>T2DM</term><def><p>Type 2 diabetes mellitus</p></def></def-item><def-item><term>UKPDS</term><def><p>UK prospective diabetes study</p></def></def-item><def-item><term>ADDITION study</term><def><p>Anglo-Danish-Dutch study of intensive treatment in people with screen-detected diabetes in primary care</p></def></def-item><def-item><term>IT</term><def><p>Intensified multi-factorial treatment</p></def></def-item><def-item><term>RC</term><def><p>Routine care</p></def></def-item><def-item><term>SF-36</term><def><p>Medical outcomes study 36-item short form health survey</p></def></def-item><def-item><term>EQ5D</term><def><p>European quality of life-5 dimensions</p></def></def-item><def-item><term>DTSQ</term><def><p>Diabetes treatment satisfaction questionnaire</p></def></def-item><def-item><term>PAID</term><def><p>Problem areas in diabetes scale</p></def></def-item></def-list></glossary></back></article>